---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-103005"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:30:59.799678+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ikena presents preclinical data for IK-930 with TEAD1 selectivity and wider therapeutic window vs panTEAD

## Summary
- IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.
- Average urinary protein-to-creatinine ratios and histopathology predicted a therapeutic index <1 for panTEAD vs broad window for IK-930.
- IK-930 plus osimertinib delayed emergence of drug-tolerant persister cells in preclinical EGFR-mutant NSCLC models.
- Phase 1 monotherapy dose escalation ongoing; initial monotherapy clinical data expected in 2H 2023.
- Cash >$155M as of filing; runway into 2025; partnered IK-175 with BMS potentially $50M opt-in fees by early 2024.

## SEC filing metadata
- accession: 0001193125-23-103005
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/0001193125-23-103005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/d460401d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-103005
- JSON: https://secwatch.observer/filing/0001193125-23-103005.json
- Plain text: https://secwatch.observer/filing/0001193125-23-103005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.